Showing results (51-60 of 230) with videos related to

Sort By:
Pageof 23
Urology|September 8, 2004
Relating biopsy and clinical variables to radical prostatectomy findings: can insignificant and advanced prostate cancer be predicted in a screening population?Jason W Anast, Gerald L Andriole, Tarek A Bismar, et al.
Urologic Oncology|July 31, 2004
The prostate, lung, colon, and ovarian (PLCO) cancer screening trial: Status and promiseGerald L Andriole, Douglas Reding, Richard B Hayes, et al.
The Journal of Urology|October 20, 2020
Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE StudyUshasi Naha, J Curtis Nickel, Gerald L Andriole, et al.
European Urology|November 25, 2010
Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trialClaus G Roehrborn, Gerald L Andriole, Timothy H Wilson, et al.
The Journal of Urology|February 21, 2012
Population based comparative effectiveness of transurethral resection of the prostate and laser therapy for benign prostatic hyperplasiaSeth A Strope, Liu Yang, Kenneth G Nepple, et al.
The Prostate|April 19, 2018
Secondary prostate cancer screening outcomes by race in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Screening TrialEric A Miller, Paul F Pinsky, Amanda Black, et al.
American Journal of Clinical Pathology|May 3, 2021
Smoking Is Associated With Basal Cell Hyperplasia on Prostate Biopsy SpecimensDaniel Melecchi Freitas, Gerald L Andriole, Stephen J Freedland, et al.
BJU International|July 6, 2013
The utility of prostate-specific antigen in the management of advanced prostate cancerE David Crawford, Charles L Bennett, Gerald L Andriole, et al.
The Prostate|July 18, 2015
Chronic baseline prostate inflammation is associated with lower tumor volume in men with prostate cancer on repeat biopsy: Results from the REDUCE studyDaniel M Moreira, J Curtis Nickel, Gerald L Andriole, et al.
Applied Health Economics and Health Policy|August 31, 2011
Cost effectiveness of chemoprevention for prostate cancer with dutasteride in a high-risk population based on results from the REDUCE clinical trialMichael W Kattan, Stephanie R Earnshaw, Cheryl L McDade, et al.
Pageof 23